Published in Blood Weekly, June 20th, 2002
The results did not demonstrate the superiority of oral heparin, when dosed in a 30-day treatment regimen, compared with Aventis' Lovenox (enoxaparin) administered by injection in a 10-day dosing regimen in preventing DVTs.
"The rigorous study design of PROTECT sought at least an absolute 10% reduction in DVT events, to claim clinical superiority to the FDA," said Russell Hull, MD, director of the Thrombosis Research Unit,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.